Trial Profile
A randomized, double-blind, placebo-controlled study of safety and efficacy of CORLUX (mifepristone) in the treatment of psychotic symptoms in patients with major depressive disorder with psychotic features.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Mifepristone (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Corcept Therapeutics
- 04 Apr 2016 Results (pooled analysis of this and other four trials, n = 1460) assessing incidence of adrenal insufficiency with normal cortisol levels presented at The 98th Annual Meeting of the Endocrine Society.
- 14 Feb 2012 Actual patient number is 257 according to ClinicalTrials.gov.
- 14 Feb 2012 Actual patient number is 257 according to ClinicalTrials.gov.